ArticleJournal of enzyme inhibition and medicinal chemistry2023
Novel multi-target ligands of dopamine and serotonin receptors for the treatment of schizophrenia based on indazole and piperazine scaffolds-synthesis, biological activity, and structural evaluation.
Article in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 8 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 4 institutions in 5 countries.
Piotr StępnickiDepartment of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy, Medical University of Lublin, Lublin, Poland.ORCID 0000-0002-3470-8248
Olga Wronikowska-DenysiukIndependent Laboratory of Behavioral Studies, Chair of Biomedical Sciences, Faculty of Biomedicine, Medical University of Lublin, Lublin, Poland.ORCID 0000-0002-9553-3664
Agata ZiębaDepartment of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy, Medical University of Lublin, Lublin, Poland.ORCID 0000-0002-8515-7482
Katarzyna M Targowska-DudaDepartment of Biopharmacy, Faculty of Pharmacy, Medical University of Lublin, Lublin, Poland.ORCID 0000-0003-4871-0848
Agata BartyzelDepartment of General and Coordination Chemistry and Crystallography, Institute of Chemical Sciences, Faculty of Chemistry, Maria Curie-Sklodowska University in Lublin, Lublin, Poland.ORCID 0000-0003-3765-6997
Martyna Z WróbelDepartment of Drug Technology and Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.ORCID 0000-0001-6201-4756
Tomasz M WróbelDepartment of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy, Medical University of Lublin, Lublin, Poland.
Klaudia SzałajDepartment of Bioanalytics, Faculty of Biomedicine, Medical University of Lublin, Lublin, Poland.ORCID 0000-0003-4962-2997
Andrzej ChodkowskiDepartment of Drug Technology and Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.
Karolina MireckaDepartment of Drug Technology and Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.
Barbara BudzyńskaIndependent Laboratory of Behavioral Studies, Chair of Biomedical Sciences, Faculty of Biomedicine, Medical University of Lublin, Lublin, Poland.ORCID 0000-0001-5917-9285
Emilia FornalDepartment of Bioanalytics, Faculty of Biomedicine, Medical University of Lublin, Lublin, Poland.ORCID 0000-0002-0503-0706
Jadwiga TurłoDepartment of Drug Technology and Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.ORCID 0000-0003-3575-8631
Marián CastroDepartment of Pharmacology, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.ORCID 0000-0002-4732-1966
Agnieszka A KaczorDepartment of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy, Medical University of Lublin, Lublin, Poland.
Medical University of Lublin · PLMedical University of Warsaw · PLMaria Curie-Skłodowska University · PLUniversidade de Santiago de Compostela · ES
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Schizophrenia is a chronic mental disorder that is not satisfactorily treated with available antipsychotics. The presented study focuses on the search for new antipsychotics by optimising the compound D2AAK3, a multi-target ligand of G-protein-coupled receptors (GPCRs), in particular D
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Novel multi-target ligands of dopamine and serotonin receptors for the treatment of schizophrenia based on indazole and piperazine scaffolds-synthesis, biological activity, and structural evaluation. · full record | OpenQuestion